Scales to Assess Psychosis in Parkinson's Disease: Critique And
Movement Disorders Vol. 23, No. 4, 2008, pp. 484–500 © 2008 Movement Disorder Society Task Force Report Scales to Assess Psychosis in Parkinson’s Disease: Critique and Recommendations Hubert H. Fernandez, MD,1* Dag Aarsland, MD,2 Gilles Fe´nelon, MD,3 Joseph H. Friedman, MD,4 Laura Marsh, MD,5 Alexander I. Tro¨ster, PhD,6 Werner Poewe, MD,7 Olivier Rascol, MD,8 Cristina Sampaio, MD,9 Glenn T. Stebbins, PhD,10 and Christopher G. Goetz, MD10 1Department of Neurology, McKnight Brain Institute/University of Florida, Gainesville, Florida, USA 2Stavanger University Hospital, Centre for Clinical Neuroscience Research, Stavanger, Norway 3Department of Neurology, Hoˆpital Henri-Mondor, Cre´til, France 4Department of Clinical Neuroscience, Brown University Medical School, Providence, Rhode Island, USA 5Department of Psychiatry, Johns Hopkins University, Baltimore, Maryland, USA 6Department of Neurology, University of North Carolina, Chapel Hill, North Carolina, USA 7Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria 8Laboratoire de Pharmacologie Medicale Et Clinique, Faculte de Medicine, Toulouse, France 9Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina de Lisboa, Lisboa, Portugal 10Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA Abstract: Psychotic symptoms are a frequent occurrence in change over time [such as the Clinical Global Impression Scale Parkinson’s disease (PD), affecting up to 50% of patients. The (CGIS)] may need to be combined with another scale better at Movement Disorder Society established a Task Force on Rat- cataloging specific features [such as the Neuropsychiatric Inven- ing Scales in PD, and this critique applies to published, peer- tory (NPI) or Schedule for Assessment of Positive Symptoms reviewed rating psychosis scales used in PD psychosis studies.
[Show full text]